Brind.

Marker Therapeutics announced that its product MT-601 showed an objective response rate of 66 percent in studies for Non-Hodgkin Lymphoma. Juan Vera serves as President and CEO.

1 report, 1 independent Updated Aug 28

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Apollo Juan Vera

Keep exploring

The entities involved

Apollo
- Past missions are informing the goals of future space programs.00:55
- A new quantum entity formed from Honeywell Quantum Solutions is targeting Apollo for a system in 2029.Wed 15:36
Juan Vera
Paraguayan professional footballer
- Marker Therapeutics, Inc., based in Houston, TX, announced that Dr. Juan Vera is the CEO and the company is participating in the Wainwright conference.Mon 12:43

Coverage

Newest first; wire copies grouped

Aug 28Insider MonkeyMarker Therapeutics (MRKR) Falls 20.6% After Positive Clinical Study We recently published 10 Stocks Losing Big. Marker Therapeutics, Inc. (NASDAQ:MRKR) is one of the worst performers of Tuesday. Mar